An innovative approach for Infectious Diseases
From clinical signatures of infection to new antivirals
Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery based on a global targeting of the host cell instead of specific viral molecular determinants.
The research strategy is based on the direct exploitation of the characterization by Next-generation sequencing of relevant in vivo transcriptomic signatures of infections and of compounds, in an innovative bedside-to-bench and bench-to-bedside approach.
Signia Therapeutics innovative approach will offer intrinsic de-risking of drug discovery process:
1) Significant cost and time reduction to validate clinical trial drug candidates
2) Enable rapid transition to phase 2 clinical trials
3) Significant shortening of response times of widespread outbreaks
4) New value-added IP opportunities
5) Rapid return on investment for drug development to market of new antivirals
Pipeline
